Although there is a dramatic improvement in patients' survival with the advent of modern immunosuppressive therapy in the field of solid organ transplantation, it is not devoid of adverse effects. Gastrointestinal (GI) manifestations are the most frequent side effects with immunosuppressive medications and occur in 40% of the recipients. [1] Drug-related acute gastritis is the most common adverse effect seen; however, with the decrease in immunity, opportunistic infections and neoplasms are frequently encountered. GI posttransplant lymphoproliferative disorder (PTLD) is a rare manifestation, seen in solid organ recipients, and can pose significant diagnostic challenges, as they present with vague symptoms, resulting in delay in diagnosis. We report a case of renal allograft recipient presenting with features of GI PTLD manifesting as chronic abdominal pain and constipation.
induction immunosuppression (mother was the donor). He was started on tacrolimus at a dose of 0.1 mg/kg/day, and the drug levels were periodically monitored. Tacrolimus drug levels persistently remained high (>10 ng/mL), requiring frequent reduction in the dose of the drug. Complete blood count, renal function tests, and liver function tests were normal and are shown in Table 1 . Stool routine examination and stool cultures were normal. The whole-blood tacrolimus trough level was 8.8 ng/mL. X-ray and ultrasonogram abdomen were normal. There was no relief of symptoms with proton-pump inhibitors and antiemetics. Computed tomography (CT) scan of the abdomen with intravenous contrast showed circumferential thickening with enhancement in the entire colon, duodenum, and terminal ileum alongside multiple subcentimetric mesenteric, para-aortic lymph nodes. In view of worsening symptoms, upper GI endoscopy was done which showed nodularity in the body of the stomach, and colonoscopy showed deep ulcers in the sigmoid colon, transverse colon, and descending colon [ Figure 1a and b]. Multiple biopsies from the lesions in the gastric antrum, transverse colon, and sigmoid colon showed surface ulcerations and diffuse and dense infiltration with atypical lymphoid cells with hyperchromatic nuclei in the lamina propria and submucosa [ Figure 2a ]. The immunohistochemistry panel for lymphoma was performed, and immunohistochemistry showed immunoexpression of B-cell markers for CD20, PAX5, CD30, BCL2, BCL6, C-myc, and MUM1 [Figures 2b-h]. The Ki-67 proliferation index of 60% was seen. The morphology and immunoprofile indicated PTLD of monomorphic type consistent with diffuse large B-cell lymphoma. The immunohistochemistry and Cytomegalovirus (CMV) DNA polymerase chain reaction (PCR) were negative for CMV. The in situ hybridization study for Epstein-Barr virus (EBV) mRNA showed strong positivity for EBV. EBV DNA PCR in the blood was strongly positive (2200 copies/mL), confirming EBV-positive PTLD. EBV serology before the transplant was positive for IgG in both the recipient and the donor indicating past infection. Bone marrow smear and biopsy were normal. Positron emission tomography-CT showed an increased fluorodeoxyglucose (FDG) uptake in the stomach and colon; there was no FDG uptake in the visceral or peripheral lymph nodes, indicating isolated GI-PTLD. The patient was treated with rituximab (dose: 375 mg/m 2 ), weekly injections for four doses, and his immunosuppressive medications (both tacrolimus and mycophenolate mofetil) were reduced by 50%. He had good symptomatic relief and did not require the use of additional chemotherapy.
discussion
GI manifestations are the most frequent drug-related side effects seen in solid organ transplantation. GI CMV infection is the most common viral infection in renal allograft recipients, which can have varied manifestations and can affect any part of the GI tract. Although there was an initial suspicion of CMV infection in our case, it was ruled out histologically and by blood tests.
PTLD is one of the most common malignancies in transplant patients, comprising 20% of all posttransplant malignancies. [2] The incidence of PTLD in kidney transplant recipients is between 1% and 3%. [3] The majority (>80%) occurs in the 1 st year posttransplant, as seen in our patient also. Rates of PTLD-associated lymphoma are higher in children than adults, owing to the relatively low rates of EBV seropositivity in pediatric population. [4] The most common manifestations of PTLD are fever and lymphadenopathy. However, extranodal PTLD is seen in two-third of the cases. [5] Isolated GI PTLD is an uncommon presentation and predominantly presents with anemia, failure to thrive, abdominal pain, and vomiting. Constipation is an uncommon manifestation, as seen in our case, posing diagnostic challenge. The colon and stomach were the most common sites involved, with rubbery, raised, and ulcerated lesions seen on endoscopy. [6] Similar findings were seen on endoscopy in our case. Approximately 85% of PTLD is of B-cell origin, and more than 80% of these are associated with EBV. [7] EBV seroconversion is an important risk factor for developing PTLD. EBV-negative recipients who receive an organ from an EBV-positive donor are at a particularly high risk for PTLD; however, in our case, both the donor and the recipient had evidence of past EBV infection. Other risk factors for PTLD include the degree and duration of immunosuppressive therapy, use of antilymphocyte therapy, CMV disease, and HLA mismatch. The degree of T-cell immunosuppression is more important than the overall immunosuppression. EBV-infected B-cells are held "in check" by cytotoxic T-cells, and impairment of T-cell function promotes the development of PTLD, particularly in children. [8] In our case, the degree of immunosuppression was persistently high as the tacrolimus levels remained high in spite of repeated revisions of the drug dose. Among maintenance immunosuppressive agents, tacrolimus has the highest risk for PTLD when compared to mycophenolate mofetil and steroids. [9, 10] Our patient had not received antilymphocyte therapy.
Treatment includes the reduction of immunosuppressive therapy and addition of anti-CD20 monoclonal antibody. In addition, chemotherapy, radiotherapy, or combination of these can be considered based on the site of the lesion. [11] Often, a reduction of 25%-50% of immunosuppression is recommended. In our case, the dose of both tacrolimus and mycophenolate mofetil was reduced by 50%, and a small dose of steroids was continued. There is no consensus on dosing recommendations for rituximab in PTLD patients. Rituximab 375 mg/m 2 /week for 4 weeks was employed in a prospective trial involving 43 patients and had overall response rates of 44%. [12] Our patient was also treated with the same regimen, and the child had a good symptomatic relief. Chemoimmunotherapy can be tried in patients with high-grade lymphoma or in those who failed to respond with rituximab alone. Rituximab in combination with chemotherapy has shown an overall response rate of 65%. [13] Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone is the commonly suggested regimen in such cases. Chemotherapy was not used in our case, as he had a good response with rituximab alone. PTLD confined to GI tract is rare; constipation as a presenting manifestation is very rare. A high index of suspicion is essential to make an early diagnosis.
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